Phase Ib/II study of LGX818 and cetuximab or LGX818, BYL719 and cetuximab in BRAF mutant mCRC
What is the purpose of this trial?
Phase Ib: To estimate the MTD and/or RP2D of LGX818 in combination with cetuximab ± BYL719
Phase II: To compare the efficacy of the dual (LGX818, cetuximab) and triple (LGX818, BYL719, cetuximab) combinations.
- 18 Years and older
- Novartis Pharmaceuticals
- Last Updated:
- Study HIC#: